Dr. Clay Siegall is the CEO of Seattle Genetics. He had founded Seattle Genetics in 1998. It was just a small startup. But under the leadership of Dr. Clay Siegall, it has become a leader in cancer research. This is because Dr. Siegall is an inspiration for many. He believes that we need to move on from the old school cancer treatment through systemic chemotherapies. This is because he is convinced about the value as well as the effectiveness of targeted therapies.
Dr. Clay Siegall has always been interested in medicine along with technology. He wants to restore the health of all those who have otherwise been consigned to death by nature. He got specifically interested in the treatment of cancer when his family member fell sick. He was shocked by the brutal treatment regimen that may have even killed him. He realized that the disease would not have caused the death, but the chemotherapy could have.
He also became aware of several other treatments that included radical surgery or amputation. This was when he decided to look for a better way to treat the disease.
Dr. Clay Siegall was working with Bristol at that time. But he did not like the constraints over there. He could not get the kind of space he wanted or the autonomy that he was looking for. Besides, he realized that he was not getting the kind of money that he deserved, though he was putting in all the efforts. Hence he decided to become his own boss.
Seattle Genetics makes money in a number of ways. They are selling their own, proprietary drugs. Their first antibody drug conjugate is FDA-approved. It has currently been approved for almost three indications. The drug is ADCetris, which is doing very well in the market.
Next are the revenues being earned through production partnerships and from licensing the technologies as well as processes that have been developed by his company. Clay Siegall did feel at times that his company may not work. This was when he saw the operating capital going down. But then he put everything behind him and got to work again.